Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue from product sales	$ 0	$ 337
Collaboration revenue	0	18
Total revenue	0	355
Cost of product sales	0	696
Cost of collaboration revenue	0	1
Total cost of revenue	0	697
Gross loss	0	(342)
Research and development expenses	6,512	8,400
Selling, general and administrative expenses	6,749	9,773
Intangible asset impairment expense	0	3,905
Restructuring costs	0	335
Operating loss	(18,981)	(26,479)
Other income (expense):
Warrant revaluation income	4,920	11,884
Derivative revaluation expense	(1,407)	(462)
Interest expense	(828)	(228)
Other income (expense), net	56	(7)
Loss before income taxes	(16,240)	(15,292)
Income tax benefit	0	0
Net loss	(16,240)	(15,292)
Dividend paid in-kind to preferred stockholders	(264)	0
Deemed dividend on preferred stock	(4,099)	0
Net loss attributable to common stockholders	$ (20,603)	$ (15,292)
Net loss
Basic (in dollars per share)	$ (1.33)	$ (1.04)
Diluted (in dollars per share)	$ (1.33)	$ (1.18)
Weighted average number of common shares outstanding
Basic (in shares)	15,454,199	14,641,528
Diluted (in shares)	15,460,118	14,647,534
Affiliated Entity
Research and development expenses	$ 5,720	$ 3,724